In a bid to reinvigorate sales of its cancer therapy Rytelo, Geron is reducing its headcount by a third and said it will use the savings to strengthen its commercial strategy and execution for the drug. The company currently has about 260 employees, so the layoffs will affect about 87 people, according to a Thursday news release.
